https://www.mithra.com/wp-content/uploads/2019/09/CP-190919.jpg 1333 2000 Mithra Pharmaceuticals https://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.png Mithra Pharmaceuticals2019-09-19 07:30:102020-07-03 11:50:17Mithra Announces 2019 Half Year Results
- Strong revenue growth from continuing operations (+191%) with best first half-year EBITDA since IPO
- Cash position remains solid at EUR 77.5 million, key for further R&D development
- Confirmed unique safety profile of Mithra’s innovative contraceptive pill Estelle® following positive results in both Europe/Russia and United States/Canada. Filing with regulatory authorities planned by end of 2019
- Phase III E4 monotherapy study of Donesta® in menopause ready to start pending agency approvals
Liege, Belgium, 19 September 2019 – 7 :30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces its financial results for the six-month period ending 30 June 2019, prepared in accordance with IFRS. The full interim report is available on the Investors section of the website.